{"id":641,"date":"2021-05-12T07:56:58","date_gmt":"2021-05-12T07:56:58","guid":{"rendered":"https:\/\/mondoconsulting.net\/?post_type=dt_portfolio&#038;p=641"},"modified":"2021-05-13T10:15:25","modified_gmt":"2021-05-13T10:15:25","slug":"pharmamar-en","status":"publish","type":"dt_portfolio","link":"https:\/\/mondoconsulting.net\/index.php\/project\/pharmamar-en\/","title":{"rendered":"Pharmamar e"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row full_width=\u00bbstretch_row\u00bb css=\u00bb.vc_custom_1620747540136{margin-top: -155px !important;padding-bottom: 65px !important;background-color: #1e73be !important;}\u00bb][vc_column][\/vc_column][\/vc_row][vc_row content_placement=\u00bbbottom\u00bb][vc_column width=\u00bb1\/2&#8243;][vc_single_image image=\u00bb372&#8243; img_size=\u00bb500&#215;500&#8243; alignment=\u00bbright\u00bb][\/vc_column][vc_column width=\u00bb1\/2&#8243;][vc_column_text]<\/p>\n<h2 style=\"text-align: left;\">PHARMAMAR<\/h2>\n<h5 class=\"p1\">Acquisition of 5% of the capital of Pharmamar (former Zeltia), the only pharma company that develops anti-cancer drugs from marine organisms.<\/h5>\n<h5 class=\"p1\">The stock value has rocketed more than 900% in the last two years.<\/h5>\n<p>[\/vc_column_text][\/vc_column][\/vc_row][vc_row content_placement=\u00bbmiddle\u00bb css=\u00bb.vc_custom_1620748185783{margin-top: 30px !important;}\u00bb][vc_column width=\u00bb1\/3&#8243;][vc_column_text]<\/p>\n<h3 style=\"text-align: center;\"><a href=\"https:\/\/mondoconsulting.net\/index.php\/project\/inditex-en\">&lt; Inditex<\/a><\/h3>\n<p>[\/vc_column_text][\/vc_column][vc_column width=\u00bb1\/3&#8243;][vc_icon icon_fontawesome=\u00bbfas fa-undo\u00bb color=\u00bbblack\u00bb size=\u00bbsm\u00bb align=\u00bbcenter\u00bb link=\u00bburl:https%3A%2F%2Fmondoconsulting.net%2Findex.php%2Fachievements%2F|title:Inicio\u00bb][\/vc_column][vc_column width=\u00bb1\/3&#8243;][vc_column_text]<\/p>\n<h3 style=\"text-align: center;\"><a href=\"https:\/\/mondoconsulting.net\/index.php\/project\/riofisa-en\">Riofisa &gt;<\/a><\/h3>\n<p>[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row full_width=\u00bbstretch_row\u00bb css=\u00bb.vc_custom_1620747540136{margin-top: -155px !important;padding-bottom: 65px !important;background-color: #1e73be !important;}\u00bb][vc_column][\/vc_column][\/vc_row][vc_row content_placement=\u00bbbottom\u00bb][vc_column width=\u00bb1\/2&#8243;][vc_single_image image=\u00bb372&#8243; img_size=\u00bb500&#215;500&#8243; alignment=\u00bbright\u00bb][\/vc_column][vc_column width=\u00bb1\/2&#8243;][vc_column_text] PHARMAMAR Acquisition of 5% of the capital of Pharmamar (former Zeltia), the only pharma company that develops anti-cancer drugs from marine organisms. The stock value has rocketed more than 900% in the last two years. [\/vc_column_text][\/vc_column][\/vc_row][vc_row content_placement=\u00bbmiddle\u00bb css=\u00bb.vc_custom_1620748185783{margin-top: 30px !important;}\u00bb][vc_column&hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","dt_portfolio_category":[23],"dt_portfolio_tags":[],"class_list":["post-641","dt_portfolio","type-dt_portfolio","status-publish","hentry","dt_portfolio_category-proyecto","dt_portfolio_category-23","description-off"],"_links":{"self":[{"href":"https:\/\/mondoconsulting.net\/index.php\/wp-json\/wp\/v2\/dt_portfolio\/641","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mondoconsulting.net\/index.php\/wp-json\/wp\/v2\/dt_portfolio"}],"about":[{"href":"https:\/\/mondoconsulting.net\/index.php\/wp-json\/wp\/v2\/types\/dt_portfolio"}],"author":[{"embeddable":true,"href":"https:\/\/mondoconsulting.net\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mondoconsulting.net\/index.php\/wp-json\/wp\/v2\/comments?post=641"}],"version-history":[{"count":3,"href":"https:\/\/mondoconsulting.net\/index.php\/wp-json\/wp\/v2\/dt_portfolio\/641\/revisions"}],"predecessor-version":[{"id":754,"href":"https:\/\/mondoconsulting.net\/index.php\/wp-json\/wp\/v2\/dt_portfolio\/641\/revisions\/754"}],"wp:attachment":[{"href":"https:\/\/mondoconsulting.net\/index.php\/wp-json\/wp\/v2\/media?parent=641"}],"wp:term":[{"taxonomy":"dt_portfolio_category","embeddable":true,"href":"https:\/\/mondoconsulting.net\/index.php\/wp-json\/wp\/v2\/dt_portfolio_category?post=641"},{"taxonomy":"dt_portfolio_tags","embeddable":true,"href":"https:\/\/mondoconsulting.net\/index.php\/wp-json\/wp\/v2\/dt_portfolio_tags?post=641"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}